Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2

Main Article Content

Richard G Langley
Jeffrey Crowley
Melinda Gooderham
Kim A Papp
Neil J Korman
Lynda Spelman
Atsuyuki Igarashi
Mamitaro Ohtsuki
Aditya K Gupta
Paul Yamauchi
Jeffrey Parno
Alan M Mendelsohn
Stephen J Rozzo
Kimberly Eads


Psoriasis, Tildrakizumab, Biologics, Safety


Abstract not available.


1) Reich K, et al. Lancet. 2017;390:276–88;

2) Blauvelt A, et al. Br J Dermatol. 2018;179:615–22.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>